Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 12:19 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1969–1992 of 3,058 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Cancer Colon Clear all

Conditions: Colorectal Cancer
Interventions: one-on-one education, group education, small media; Behavioral
Lead sponsor: Centers for Disease Control and Prevention; Federal
Eligibility: 50 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001 – 2005
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
Interventions: 5-year and 10 Year Surveillance Colonoscopy after Qualifying Colonoscopy; Procedure
Lead sponsor: NRG Oncology; Other
Eligibility: 45 Years to 70 Years
Enrollment: 9,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2065
U.S. locations: 484
States / cities: Fairbanks, Alaska • Goodyear, Arizona • Kingman, Arizona + 328 more

Conditions: Melanoma, Cervical Carcinoma, Pancreatic Carcinoma, Triple Negative Breast Cancer, Hepatocellular Carcinoma, Urothelial Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Nasopharyngeal Carcinoma, Renal Cell Carcinoma, Non-small Cell Lung Carcinoma, Small Cell Lung Carcinoma, Gastric or Gastroesophageal Junction Adenocarcinoma, Advanced or Metastatic Solid Tumors, Prostate Carcinoma, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Intrahepatic Cholangiocarcinoma, Squamous Cell Anal Cancer, Squamous Cell Penile Carcinoma, Squamous Cell Vulvar Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma
Interventions: XmAb®22841, Pembrolizumab (Keytruda®); Biological
Lead sponsor: Xencor, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 28
States / cities: Encinitas, California • La Jolla, California • Los Angeles, California + 15 more

Conditions: Colorectal Cancer Screening, Colon Adenomatous Polyp
Interventions: Ambient lighting, Low lighting; Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 1,109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Park Ridge, Illinois

Conditions: Neuropathy, Painful, Chemotherapy-induced Peripheral Neuropathy, Colorectal Cancer
Interventions: Lidocaine Hydrochloride, Placebo, FOLFOX regimen; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Colorectal Cancer
Interventions: Magnesium glycinate, Placebo; Dietary Supplement
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 40 Years to 85 Years
Enrollment: 250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2025
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Colorectal Cancer
Interventions: irofulven; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2000
U.S. locations: 9
States / cities: Chicago, Illinois • Decatur, Illinois • Park Ridge, Illinois + 4 more

Conditions: Colorectal Cancer
Interventions: cf-circRNA assay; Diagnostic Test
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Duarte, California

Conditions: Colorectal Cancer
Interventions: Vitamin D intervention, Placebo intervention; Dietary Supplement
Lead sponsor: Baylor University; Other
Eligibility: 18 Years to 79 Years
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Waco, Texas

Conditions: Inherited Cancer Syndrome, Prostate Cancer, Colorectal Cancer, Endometrial Cancer, Breast Cancer
Interventions: Correlative Studies (Survey), Correlative Studies (Interview), GeneSHARE, LivingLabReport, Standard-of-care & Adaptive Intervention, Access to Education Materials; Other · Behavioral
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 720 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Melanoma, Colonic Neoplasms, Breast Neoplasms
Interventions: PD-0325901; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2013
U.S. locations: 17
States / cities: Birmingham, Alabama • La Jolla, California • La Mesa, California + 8 more

Conditions: Metastatic Colorectal Cancer
Interventions: Rivoceranib, Trifluridine/Tipiracil; Drug
Lead sponsor: Elevar Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 4
States / cities: Sarasota, Florida • Chicago, Illinois • St Louis, Missouri + 1 more

Conditions: Anal Cancer, Colorectal Cancer, Drug/Agent Toxicity by Tissue/Organ, Radiation Enteritis
Interventions: octreotide acetate, Placebo; Drug · Other
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years to 120 Years
Enrollment: 233 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 112
States / cities: Mobile, Alabama • Phoenix, Arizona • Chico, California + 89 more

Conditions: Gastrointestinal Cancer, Pancreatic Cancer, Gastric Cancer, Colon Cancer, Rectal Cancer
Interventions: Cyclophosphamide, Fludarabine, Aldesleukin, anti-Kirsten rat sarcoma virus (KRAS) Glycine(G) to Aspartic Acid(D) substitution at codon 12 peripheral blood lymphocytes (PBL), EKG, CT, MRI, PET, Chest x-ray, Photography; Drug · Biological · Diagnostic Test + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 72 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Neuroendocrine Tumors, Brain (Nervous System) Cancers, Colon/Rectal Cancer, Colon Cancer, Hepatobiliary Cancers, Hepatocellular Carcinoma (Hepatoma), Liver
Interventions: CT perfusion; Procedure
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: Stanford, California

Conditions: MUC17-positive Solid Tumors
Interventions: AMG 199; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 3
States / cities: Duarte, California • Orange, California • Winston-Salem, North Carolina

Conditions: Carcinoma, Non-Small-Cell Lung, Carcinoma, Colorectal
Interventions: Pembrolizumab Injection; Drug
Lead sponsor: Persephone Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 2
States / cities: Fountain Valley, California • Winter Haven, Florida

Conditions: Neoplasms
Interventions: Encorafenib, Cetuximab, Oxaliplatin, Irinotecan, Leucovorin, 5-FU, Capecitabine, Bevacizumab; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 16 Years and older
Enrollment: 841 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 62
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 38 more

Conditions: Advanced Colorectal Cancer
Interventions: Paclitaxel Poliglumex; Drug
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older · Female only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Breast Cancer, Colon Cancer, Lung Cancer, Skin Cancer, Rectum Cancer
Interventions: Automated Telephone Symptom Management (ATMS) and Telephone Interpersonal Counseling (TIP-C), Active control comparator; Behavioral
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 3
States / cities: Phoenix, Arizona • Tucson, Arizona • Ann Arbor, Michigan

Conditions: Cancer, Breast Cancer, Colorectal Cancer
Interventions: Health Newsletter; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 50 Years to 70 Years
Enrollment: 15,824 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Advanced Colorectal Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Melanoma, Advanced Renal Cell Carcinoma, Advanced Triple-Negative Breast Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer (AJCC) v8, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage III Renal Cell Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Interventions: Fermented Wheat Germ Extract; Drug
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Colorectal Polyp, Colorectal Neoplasms, Colorectal Adenoma, Colorectal Cancer, Digestive System Disease
Interventions: FIT, Colonoscopy; Diagnostic Test
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 65 Years to 82 Years
Enrollment: 6,434 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2035
U.S. locations: 20
States / cities: Birmingham, Alabama • Tucson, Arizona • San Diego, California + 17 more

Conditions: Colorectal Cancer
Interventions: FOLFIRI, RO5083945, cetuximab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 169 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 16
States / cities: Encinitas, California • Highland, California • La Jolla, California + 11 more

Search by objective public record fields.

Colorectal Cancer Control in Appalachian Churches

Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps

A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors

Ambient Lighting During Colonoscopy and Its Effect on Adenoma Detection Rate and Eye Fatigue

Lidocaine for Oxaliplatin-induced Neuropathy

Precision-Based Magnesium Trial

Irofulven in Treating Patients With Metastatic or Recurrent Colorectal Cancer

Liquid Biopsy for Early Detection of Colorectal Cancer Using Circular RNA

Vitamin D Intervention and Associated Changes in the Gut Microbiome and Vitamin D Levels in Healthy Adults

Improving Care After Inherited Cancer Testing

MEK Inhibitor PD-325901 To Treat Advanced Breast Cancer, Colon Cancer, And Melanoma.

A Study of Rivoceranib and Trifluridine/Tipiracil for Metastatic Colorectal Cancer (mCRC)

Octreotide in Preventing or Reducing Diarrhea in Patients Receiving Chemoradiotherapy for Anal or Rectal Cancer

Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients

Perfusion CT as a Predictor of Treatment Response in Patients With Hepatic Malignancies

Study of AMG 199 in Subjects With MUC17-Positive Solid Tumors Including Gastric, Gastroesophageal Junction, Colorectal, and Pancreatic Cancers

Development and Analysis of a Stool Bank for Cancer Patients

A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer

A Pilot Study of PPX in Women With Metastatic Colorectal Cancer

Adaptive Symptom Self-Management Immunotherapy Study

RCT to Examine the Effects of Scanning

The Immune Effects of Fermented Wheat Germ Nutritional Supplementation in Patients With Advanced Solid Tumor Cancers Being Treated With Standard of Care Checkpoint Inhibitors

Colonoscopy vs Stool Testing for Older Adults With Colon Polyps

A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer